CN114096543A - 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用 - Google Patents

核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用 Download PDF

Info

Publication number
CN114096543A
CN114096543A CN202180002969.0A CN202180002969A CN114096543A CN 114096543 A CN114096543 A CN 114096543A CN 202180002969 A CN202180002969 A CN 202180002969A CN 114096543 A CN114096543 A CN 114096543A
Authority
CN
China
Prior art keywords
radical
alkyl
virus
compound
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180002969.0A
Other languages
English (en)
Other versions
CN114096543B (zh
Inventor
谢元超
肖庚富
何洋
张磊砢
蒋华良
沈敬山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Wangshan Wangshui Biopharmaceutical Co ltd
Shanghai Institute of Materia Medica of CAS
Xinjiang Technical Institute of Physics and Chemistry of CAS
Wuhan Institute of Virology of CAS
Original Assignee
Suzhou Vigonvita Life Sciences Co ltd
Shanghai Institute of Materia Medica of CAS
Wuhan Institute of Virology of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Vigonvita Life Sciences Co ltd, Shanghai Institute of Materia Medica of CAS, Wuhan Institute of Virology of CAS filed Critical Suzhou Vigonvita Life Sciences Co ltd
Priority to CN202211058832.XA priority Critical patent/CN115448924B/zh
Publication of CN114096543A publication Critical patent/CN114096543A/zh
Application granted granted Critical
Publication of CN114096543B publication Critical patent/CN114096543B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/005—Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

本发明涉及核苷类似物在抗病毒中的应用。具体而言，本发明涉及核苷类似物及其药物组合物作为(a)抑制冠状病毒、流感病毒、呼吸道合胞病毒、黄病毒科病毒、丝状病毒科病毒和/或猪流行性腹泻病毒(PEDV)复制的抑制剂；和/或(b)治疗和/或预防、缓解由冠状病毒、流感病毒、呼吸道合胞病毒、黄病毒科病毒、丝状病毒科病毒和/或猪流行性腹泻病毒(PEDV)感染引起的相关疾病的药物中的用途。本发明的核苷类似物可治疗和/或预防、缓解由2019新型冠状病毒感染引起的呼吸道感染、肺炎(COVID‑19)等相关疾病。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN202180002969.0A 2020-04-20 2021-04-16 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用 Active CN114096543B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211058832.XA CN115448924B (zh) 2020-04-20 2021-04-16 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202010313870X 2020-04-20
CN202010313870 2020-04-20
CN202010568329 2020-06-19
CN2020105683293 2020-06-19
CN2020110350651 2020-09-27
CN202011035065.1A CN112778310A (zh) 2020-04-20 2020-09-27 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
PCT/CN2021/087928 WO2021213288A1 (zh) 2020-04-20 2021-04-16 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211058832.XA Division CN115448924B (zh) 2020-04-20 2021-04-16 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用

Publications (2)

Publication Number Publication Date
CN114096543A true CN114096543A (zh) 2022-02-25
CN114096543B CN114096543B (zh) 2022-08-16

Family

ID=75750428

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202011035065.1A Pending CN112778310A (zh) 2020-04-20 2020-09-27 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN202180002969.0A Active CN114096543B (zh) 2020-04-20 2021-04-16 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN202211058832.XA Active CN115448924B (zh) 2020-04-20 2021-04-16 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202011035065.1A Pending CN112778310A (zh) 2020-04-20 2020-09-27 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202211058832.XA Active CN115448924B (zh) 2020-04-20 2021-04-16 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用

Country Status (12)

Country Link
US (2) US11919923B2 (zh)
EP (1) EP4141007A1 (zh)
JP (1) JP2023526179A (zh)
KR (1) KR20220143919A (zh)
CN (3) CN112778310A (zh)
AU (1) AU2021260618B2 (zh)
BR (1) BR112022021226A2 (zh)
CA (1) CA3171091A1 (zh)
CO (1) CO2022015415A2 (zh)
IL (1) IL297410A (zh)
MX (1) MX2022013270A (zh)
WO (1) WO2021213288A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114796177A (zh) * 2022-06-27 2022-07-29 广州国家实验室 抗冠状病毒药物和应用
WO2023174162A1 (zh) * 2022-03-18 2023-09-21 苏州旺山旺水生物医药有限公司 一种四异丁酰基核苷类似物的制备方法及用途
WO2023202604A1 (zh) * 2022-04-20 2023-10-26 中国科学院上海药物研究所 抗病毒核苷类似物及其药物组合物和用途
US11919923B2 (en) 2020-04-20 2024-03-05 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Antiviral application of nucleoside analog or combination formulation containing nucleoside analog

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10675296B2 (en) 2017-07-11 2020-06-09 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
CN114641299A (zh) 2020-01-27 2022-06-17 吉利德科学公司 用于治疗SARS CoV-2感染的方法
JP2023516087A (ja) 2020-03-12 2023-04-17 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノヌクレオシドを調製する方法
US11701372B2 (en) 2020-04-06 2023-07-18 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs
AU2021281351A1 (en) 2020-05-29 2023-01-19 Gilead Sciences, Inc. Remdesivir treatment methods
BR112022026321A2 (pt) 2020-06-24 2023-01-17 Gilead Sciences Inc Análogos de 1'-ciano nucleosídeo e usos dos mesmos
PT4204421T (pt) 2020-08-27 2024-06-25 Gilead Sciences Inc Compostos e métodos para o tratamento de infeções virais
WO2022089302A1 (zh) * 2020-10-26 2022-05-05 苏州旺山旺水生物医药有限公司 一种核苷类似物的盐及其晶型、药物组合物和用途
EP4234557A4 (en) * 2020-10-26 2024-05-15 Vigonvita Life Sciences Co., Ltd. NUCLEOSIDE ANALOGUE SALT AND CRYSTALLINE FORM THEREOF, PHARMACEUTICAL COMPOSITION AND USE
KR20230127294A (ko) * 2020-12-30 2023-08-31 서던 유니버시티 오브 사이언스 앤드 테크놀로지 코로나 바이러스 감염을 치료하기 위한 방법 및 변형된뉴클레오사이드
CN113105504B (zh) * 2021-03-30 2024-06-04 澳门科技大学 Remdesivir衍生物、其类似物及其制备方法与应用
CN114765979A (zh) * 2021-04-23 2022-07-19 苏州旺山旺水生物医药有限公司 一种核苷类化合物及其在治疗猫传染性腹膜炎中的应用
CN113185519A (zh) * 2021-04-23 2021-07-30 苏州富德兆丰生化科技有限公司 一种核苷类化合物及其在治疗猫传染性腹膜炎中的应用
CN113698405B (zh) * 2021-06-03 2022-09-27 南方科技大学坪山生物医药研究院 一种核苷类化合物的晶型及其制备方法
TW202317144A (zh) 2021-06-14 2023-05-01 美商維納拓爾斯製藥公司 口服生物可利用的核苷類似物
JPWO2023022216A1 (zh) 2021-08-20 2023-02-23
EP4410788A1 (en) * 2021-09-30 2024-08-07 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Cyano compound, and preparation method therefor and use thereof
CN113999237B (zh) * 2021-10-29 2023-08-08 润佳（苏州）医药科技有限公司 一种核苷类前药及其用途
EP4417608A1 (en) * 2021-11-04 2024-08-21 Shenzhen Antiv Pharma Co., Ltd. Crystal form of isobutyrate nucleoside compound, and preparation method
CN116262110A (zh) * 2021-12-13 2023-06-16 苏州旺山旺水生物医药有限公司 口服氘代核苷或其可药用盐的药物组合物及制备方法和应用
CN117886872A (zh) * 2021-12-15 2024-04-16 南京知和医药科技有限公司 一种抗病毒感染的嘌呤核苷衍生物及其药物组合物和用途
CN114933600B (zh) * 2021-12-23 2023-06-27 深圳安泰维生物医药有限公司 一种核苷类化合物的晶型
CN114181258B (zh) * 2021-12-29 2023-10-13 南京师范大学 用于抗病毒治疗的核苷类化合物及用途
CN114605419A (zh) * 2021-12-30 2022-06-10 威科检测集团有限公司 一种具有抗新冠病毒活性的吡咯烷类化合物及其在药物中的应用
CN114516875B (zh) * 2022-01-26 2023-07-21 苏州旺山旺水生物医药有限公司 一种核苷类似物vv116的制备方法
WO2023167944A1 (en) 2022-03-02 2023-09-07 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
TW202345786A (zh) * 2022-03-02 2023-12-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
WO2023168254A1 (en) * 2022-03-03 2023-09-07 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
CN114504578A (zh) * 2022-03-03 2022-05-17 苏州旺山旺水生物医药有限公司 治疗、预防由病毒感染引起的相关疾病的药物及其用途
WO2023186026A1 (zh) * 2022-03-31 2023-10-05 苏州旺山旺水生物医药有限公司 一种单异丁酰基核苷类似物的制备方法
TW202345800A (zh) * 2022-04-06 2023-12-01 美商維納拓爾斯製藥公司 口服生物可利用的核苷類似物
CN114644651A (zh) * 2022-04-13 2022-06-21 中国人民解放军军事科学院军事医学研究院 芳氧基磷酰化氨基酸酯化合物的制备方法
CN114869893B (zh) * 2022-04-15 2023-09-15 苏州旺山旺水生物医药有限公司 一种药物组合物及其应用
WO2023207942A1 (zh) * 2022-04-25 2023-11-02 北京沐华生物科技有限责任公司 用于治疗或预防冠状病毒感染的核苷类药物及其用途
CN114917233B (zh) * 2022-05-05 2023-09-19 苏州旺山旺水生物医药有限公司 一种包含核苷类似物的药物组合物及其制备方法和应用
CN117440952A (zh) * 2022-05-17 2024-01-23 南京明德新药研发有限公司 氘代核苷化合物及其应用
CN116850192A (zh) * 2022-05-27 2023-10-10 深圳安泰维生物医药有限公司 一种核苷类衍生化合物的药物组合物及其制备方法和用途
US20240009220A1 (en) 2022-06-06 2024-01-11 Gilead Sciences, Inc. Methods for treatment of viral infections
CN117298120A (zh) * 2022-06-28 2023-12-29 苏州旺山旺水生物医药股份有限公司 一种治疗猫冠状或杯状病毒感染的方法
TW202408511A (zh) 2022-08-05 2024-03-01 美商基利科學股份有限公司 Ｓａｒｓ－ｃｏｖ２主蛋白酶抑制劑
CN117503776A (zh) * 2022-08-05 2024-02-06 临港国家实验室 一种药物组合物及其用途
WO2024054618A1 (en) 2022-09-09 2024-03-14 Gilead Sciences, Inc. Methods for treatment of viral infections
WO2024076951A2 (en) * 2022-10-04 2024-04-11 The Scripps Research Institute Antiviral prodrugs and formulations thereof
WO2024088183A1 (en) * 2022-10-23 2024-05-02 Shanghai Curegene Pharmaceutical Co., Ltd. Anticoronviral compounds and compositions and uses thereof
WO2024088184A1 (en) * 2022-10-23 2024-05-02 Shanghai Curegene Pharmaceutical Co., Ltd. Anti-feline-coronavirus compounds and uses thereof
TW202417009A (zh) 2022-10-27 2024-05-01 美商基利科學股份有限公司 醫藥配方及其用途
CN118165034A (zh) * 2022-12-09 2024-06-11 深圳市塔吉瑞生物医药有限公司 核苷酸类化合物及其组合物及用途
WO2024129963A1 (en) * 2022-12-14 2024-06-20 VenatoRx Pharmaceuticals, Inc. Orally-bioavailable nucleoside analogs
WO2024153020A1 (zh) * 2023-01-16 2024-07-25 海南先声药业有限公司 抗病毒药物组合物及其制备方法
CN116217621B (zh) * 2023-04-26 2023-08-11 北京沐华生物科技有限责任公司 一种核苷类双前药、合成方法及应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102015714A (zh) * 2008-04-23 2011-04-13 吉里德科学公司 用于抗病毒治疗的1’-取代的carba-核苷类似物
CN107073005A (zh) * 2014-10-29 2017-08-18 吉利德科学公司 治疗丝状病毒科病毒感染的方法
CN108137641A (zh) * 2015-08-13 2018-06-08 默沙东公司 作为sting激动剂的环状双核苷酸化合物
CN108348526A (zh) * 2015-09-16 2018-07-31 吉利德科学公司 治疗沙粒病毒科和冠状病毒科病毒感染的方法
WO2019053696A1 (en) * 2017-09-18 2019-03-21 Alios Biopharma, Inc. SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF
CN109748944A (zh) * 2017-11-03 2019-05-14 中国科学院上海药物研究所 5’-脱氧-5’-异丙基取代氨基核苷类化合物、其制备方法和用途
CN111620909A (zh) * 2020-06-05 2020-09-04 广东中科药物研究有限公司 一种瑞德西韦的前体药物及其制备方法与应用
CN113248508A (zh) * 2020-02-13 2021-08-13 安徽诺全药业有限公司 N-保护的杂环类化合物、其制备方法及其用于制备c-核苷衍生物的方法
CN113387954A (zh) * 2020-03-11 2021-09-14 上海特化医药科技有限公司 一种瑞德西韦中间体的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011035250A1 (en) * 2009-09-21 2011-03-24 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
TW201201815A (en) * 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
KR20190141747A (ko) 2017-05-01 2019-12-24 길리애드 사이언시즈, 인코포레이티드 (S)-2-에틸부틸 2-(((S)-(((2R,3S,4R,5R)-5-(4-아미노피롤로[2,1-f] [1,2,4]트리아진-7-일)-5-시아노-3,4-디히드록시테트라히드로푸란-2-일)메톡시)(페녹시) 포스포릴)아미노)프로파노에이트의 결정질 형태
CN110330540A (zh) * 2019-08-08 2019-10-15 木天(济南)生物科技有限公司 核苷盐及其制备方法
CN111135184A (zh) * 2020-03-05 2020-05-12 华中农业大学 GS-441524在制备新型冠状病毒SARS-CoV-2抑制剂中的应用
CN112778310A (zh) 2020-04-20 2021-05-11 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102015714A (zh) * 2008-04-23 2011-04-13 吉里德科学公司 用于抗病毒治疗的1’-取代的carba-核苷类似物
CN107073005A (zh) * 2014-10-29 2017-08-18 吉利德科学公司 治疗丝状病毒科病毒感染的方法
CN108137641A (zh) * 2015-08-13 2018-06-08 默沙东公司 作为sting激动剂的环状双核苷酸化合物
CN108348526A (zh) * 2015-09-16 2018-07-31 吉利德科学公司 治疗沙粒病毒科和冠状病毒科病毒感染的方法
WO2019053696A1 (en) * 2017-09-18 2019-03-21 Alios Biopharma, Inc. SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF
CN109748944A (zh) * 2017-11-03 2019-05-14 中国科学院上海药物研究所 5’-脱氧-5’-异丙基取代氨基核苷类化合物、其制备方法和用途
CN113248508A (zh) * 2020-02-13 2021-08-13 安徽诺全药业有限公司 N-保护的杂环类化合物、其制备方法及其用于制备c-核苷衍生物的方法
CN113387954A (zh) * 2020-03-11 2021-09-14 上海特化医药科技有限公司 一种瑞德西韦中间体的制备方法
CN111620909A (zh) * 2020-06-05 2020-09-04 广东中科药物研究有限公司 一种瑞德西韦的前体药物及其制备方法与应用

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AESOP CHO ET AL.: "Synthesis and antiviral activity of a series of 1’–substituted 4-aza-7,9-dideazaadenosine C-nucleosides", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *
BRIAN A. OTTER ET AL.: "Conformational properties of purine-like c-nucleosides", 《NUCLEOSIDES AND NUCLEOTIDES》 *
JINGYUE JU ET AL.: "Nucleotide Analogues as Inhibitors of SARS-CoV Polymerase", 《BIORXIV》 *
MANLI WANG ET AL.: "Remdesivir and chloroquine effectively inhibit the recently", 《CELL RESEARCH》 *
QINGFENG LI ET AL.: "Anti-norovirus activity of C7-modified 4-amino-pyrrolo[2,1-f][1,2,4] triazine C-nucleosides", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 *
QINGFENG LI ET AL.: "Synthesis and biological evaluation of pyrrolo[2,1-f][1,2,4]triazine C-nucleosides with a ribose, 2’-deoxyribose and 2’,3’-dideoxyribose sugar moiety", 《CHEMMEDCHEM》 *
江文峰 等: "氘代作用在药物研究中的应用", 《齐鲁药事》 *
王浩丹 等: "《生物医学标记示踪技术》", 31 December 1995 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11919923B2 (en) 2020-04-20 2024-03-05 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Antiviral application of nucleoside analog or combination formulation containing nucleoside analog
WO2023174162A1 (zh) * 2022-03-18 2023-09-21 苏州旺山旺水生物医药有限公司 一种四异丁酰基核苷类似物的制备方法及用途
WO2023202604A1 (zh) * 2022-04-20 2023-10-26 中国科学院上海药物研究所 抗病毒核苷类似物及其药物组合物和用途
CN114796177A (zh) * 2022-06-27 2022-07-29 广州国家实验室 抗冠状病毒药物和应用

Also Published As

Publication number Publication date
CA3171091A1 (en) 2021-10-28
AU2021260618A8 (en) 2022-10-27
IL297410A (en) 2022-12-01
KR20220143919A (ko) 2022-10-25
US11919923B2 (en) 2024-03-05
CN115448924A (zh) 2022-12-09
JP2023526179A (ja) 2023-06-21
AU2021260618A1 (en) 2022-10-06
BR112022021226A2 (pt) 2022-12-06
MX2022013270A (es) 2023-01-05
CN112778310A8 (zh) 2021-07-30
CN114096543B (zh) 2022-08-16
CN112778310A (zh) 2021-05-11
EP4141007A1 (en) 2023-03-01
AU2021260618B2 (en) 2024-05-02
US20240140975A1 (en) 2024-05-02
US20230219993A1 (en) 2023-07-13
WO2021213288A1 (zh) 2021-10-28
CN115448924B (zh) 2024-06-18
CO2022015415A2 (es) 2023-02-27

Similar Documents

Publication Publication Date Title
CN114096543B (zh) 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
EP3459926B1 (en) Phenylate derivative, preparation method therefor, and pharmaceutical composition and uses thereof
CN115215914B (zh) 核苷类似物及其用途
WO2020030143A1 (zh) 酮酰胺类化合物及其制备方法、药物组合物和用途
CN111557939B (zh) 法匹拉韦在制备用于治疗冠状病毒感染的药物中的应用
CN105849100B (zh) 流感病毒复制抑制剂
US10583129B2 (en) Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
WO2020241759A1 (ja) インフルエンザウイルス感染症またはコロナウイルス感染症の予防および／または治療剤
JP2013541519A (ja) 抗ウイルス治療用の２’−フルオロ置換カルバヌクレオシド類似体
CN107567442B (zh) C型肝炎病毒聚合酶的抑制剂
US20220233468A1 (en) Methods for treating coronavirus infection
CN113444075B (zh) 二氢吲哚衍生物、及其制法和药物组合物与用途
WO2013131496A1 (zh) 治疗病毒疾病的成分和方法
CN114805141A (zh) 4-胍基苯甲酸芳基酯类化合物及其在抗SARS-CoV-2病毒中的用途
CN113952457A (zh) 泰瑞米特或含有泰瑞米特的药物组合物在抗冠状病毒中的应用
TW200410923A (en) Therapeutic agent for chronic obstructive pulmonary disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Xie Yuanchao

Inventor after: Xiao Gengfu

Inventor after: He Yang

Inventor after: Zhang Leichang

Inventor after: Agui Iqbal Isa

Inventor after: Jiang Hualiang

Inventor after: Shen Jingshan

Inventor before: Xie Yuanchao

Inventor before: Xiao Gengfu

Inventor before: He Yang

Inventor before: Zhang Leichang

Inventor before: Jiang Hualiang

Inventor before: Shen Jingshan

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20220824

Address after: 201203 555 Zhangjiang Road, Zhangjiang, Pudong New Area, Shanghai

Patentee after: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Patentee after: Wuhan Institute of Virology, Chinese Academy of Sciences

Patentee after: XINJIANG TECHNICAL INSTITUTE OF PHYSICS & CHEMISTRY, CHINESE ACADEMY OF SCIENCES

Patentee after: SUZHOU VIGONVITA LIFE SCIENCES Co.,Ltd.

Address before: 201203 555 Zhangjiang Road, Zhangjiang, Pudong New Area, Shanghai

Patentee before: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Patentee before: Wuhan Institute of Virology, Chinese Academy of Sciences

Patentee before: SUZHOU VIGONVITA LIFE SCIENCES Co.,Ltd.

CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: 201203 555 Zhangjiang Road, Zhangjiang, Pudong New Area, Shanghai

Patentee after: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Country or region after: China

Patentee after: Wuhan Institute of Virology, Chinese Academy of Sciences

Patentee after: XINJIANG TECHNICAL INSTITUTE OF PHYSICS & CHEMISTRY, CHINESE ACADEMY OF SCIENCES

Patentee after: Suzhou Wangshan Wangshui Biopharmaceutical Co.,Ltd.

Address before: 201203 555 Zhangjiang Road, Zhangjiang, Pudong New Area, Shanghai

Patentee before: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Country or region before: China

Patentee before: Wuhan Institute of Virology, Chinese Academy of Sciences

Patentee before: XINJIANG TECHNICAL INSTITUTE OF PHYSICS & CHEMISTRY, CHINESE ACADEMY OF SCIENCES

Patentee before: SUZHOU VIGONVITA LIFE SCIENCES Co.,Ltd.